circular Sharon Ayd, PhD, MBA headshot on gray background

Sharon Ayd, Ph.D., MBA

Chief Regulatory Officer, 32 Biosciences

Sharon Ayd serves as Chief Regulatory Officer of 32 Biosciences. She brings over 35 years of leadership in strategic planning, operations, R&D, clinical development, and regulatory strategy within the biopharma industry. With deep expertise in navigating complex regulatory landscapes, she specializes in the development of small molecules, therapeutic proteins, biosimilars, and drug/device combination products across diverse indications. Sharon also provides strategic guidance in mergers and acquisitions, business development, and due diligence.

 

An entrepreneurial executive and experienced Board Director, Dr. Ayd is dedicated to driving business success by applying her comprehensive knowledge to guide effective execution. As the Founder & CEO of Ayd BioPharma Consulting Group, LLC, she serves as a trusted advisor to life sciences companies, supporting them from the nonclinical phase through clinical development, regulatory approval, product launch, and lifecycle management. Her leadership has contributed to the approval of approximately 90 drug applications globally, generating billions in revenue.

Before joining 32 Biosciences, Dr. Ayd held executive roles at major biopharma companies. At Fresenius Kabi (FRE:DAX), she served as Vice President of Innovation & Development, overseeing a $2.5 billion sterile injectable drug pipeline for North America. As Global Vice President and a key executive at Hospira (HSP:NYSE), now part of Pfizer (PFE:NYSE), she led R&D-focused due diligence for notable M&A deals, including the $2 billion acquisition of Mayne Pharma Ltd. and the $1 billion acquisition of Orchid Pharmaceuticals. Following the Orchid acquisition, she led the development of a new R&D center in India, integrating it with global teams across four continents. Her career also includes leadership roles at biotech startups, including Chief Operating Officer at Advanced Life Sciences (ADLS:NASDAQ) and Chief Scientific Officer at Pinnacle Biologics.

Beyond her role at 32 Biosciences, Dr. Ayd serves as an Adjunct Professor of Law at Northwestern University’s Pritzker School